Literature, news and videos pertinent to
The Brian Allman Diffuse Large B Cell Lymphoma (DLBCL) Novel Therapeutics Program
Bianca Santomasso, MD, PhD, on ASCO's Guidelines on Safe Management of CAR T Cells—Medpagetoday
Bispecific antibodies for non-Hodgkin's lymphomas and multiple myeloma—NIH National Library of Medicine
powered by Surfing Waves
The Brian Allman Diffuse Large B Cell Lymphoma (DLBCL) Novel Therapeutics Program
is a vital part of ICAN's Cancer Patient Advocacy and Clinical Trials Program Advocacy Services.
We also accept PayPal
paypal.me/ICANadvocacy
Federal Tax I.D.: EIN 86-0818253